Jazz Pharmaceuticals(JAZZ) - 2024 Q1 - Earnings Call Presentation

• Expanded field force to increase the breadth of IH prescribers 9,050 9,300 9,500 9,525 9,900 2,000 2,200 2,550 2,775 3,050 Narcolepsy IH 12,050 11,050 11,500 12,300 12,950 ACTIVE XYWAV PATIENTS1 1Q23 2Q23 3Q23 4Q23 1Q24 Sleep Franchise • Total 1Q24 sleep revenue of $430 2 million • Expect high-sodium AG royalty revenue to exceed$200M in 2024 Expect Xywav to Remain Oxybate of Choice • Revenue grew 14% YoY Narcolepsy • Benefits of reducing sodium intake and an individualized dosing regimen continue to reso ...